L. G. Lima (1), A. S. Oliveira (1), L. C. Campos (2), M. Bonamino (2), R. Chammas (3), C. Werneck (4), C. P. Vicente (5), M. A. Barcinski (6), L. C. Petersen (7), R. Q. Monteiro (1)
(1) Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; (2) Division of Experimental Medicine, National Cancer Institute, Rio de Janeiro, Brazil; (3) Laboratory of Experimental Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil; (4) Department of Anatomy, Cell Biology and Physiology and Biophysics, Institute of Biology, University of Campinas, São Paulo, Brazil; (5) Department of Biochemistry, Institute of Biology, University of Campinas, São Paulo, Brazil; (6) Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; (7) Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv, Denmark
Shedding of microvesicles (MVs) by cancer cells is implicated in a variety of biological effects, including the establishment of cancer-associated hypercoagulable states. However, the mechanisms underlying malignant transformation and the acquisition of procoagulant properties by tumour-derived MVs are poorly understood. Here we investigated the procoagulant and prothrombotic properties of MVs produced by a melanocyte-derived cell line (melan-a) as compared to its tumourigenic melanoma counterpart Tm1. Tumour cells exhibit a two-fold higher rate of MVs production as compared to melan-a. Melanoma MVs display greater procoagulant activity and elevated levels of the clotting initiator protein tissue factor (TF). On the other hand, tumour- and melanocyte-derived MVs expose similar levels of the procoagulant lipid phosphatidylserine, displaying identical abilities to support thrombin generation by the prothrombinase complex. By using an arterial thrombosis model, we observed that melanoma- but not melanocyte-derived MVs strongly accelerate thrombus formation in a TF-dependent manner, and accumulate at the site of vascular injury. Analysis of plasma obtained from melanoma-bearing mice showed the presence of MVs with a similar procoagulant pattern as compared to Tm1 MVs produced in vitro. Remarkably, flow-cytometric analysis demonstrated that 60% of ex vivo MVs are TF-positive and carry the melanoma-associated antigen, demonstrating its tumour origin. Altogether our data suggest that malignant transformation in melanocytes increases the production of procoagulant MVs, which may contribute for a variety of coagulation-related protumoural responses.
cancer, thrombosis, Microvesicles, melanocyte transformation
J. Emmerechts (1), M. F. Hoylaerts (1)
Hämostaseologie 2012 32 1: 5-13
Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor
F. Langer (1), C. Bokemeyer (1)
Hämostaseologie 2012 32 2: 95-104
Systemic or local control of coagulation?
M. Vasse (1)
Hämostaseologie 2011 31 3: 155-164
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...